Ozempic Lawsuit 2026: Stomach Paralysis, Vision Loss, and a Litigation That Is Moving Fast

Ozempic became a cultural phenomenon almost overnight. Prescribed for type 2 diabetes, embraced for weight loss, endorsed everywhere from celebrity interviews to social media feeds. Millions of people started taking it. Novo Nordisk's revenue soared.

And then the reports started coming in.

Stomach paralysis. Bowel obstruction. Sudden vision loss. Injuries that were not listed prominently on the label. Conditions that did not go away when patients stopped the drug.

As of May 2026, more than 3,500 lawsuits are consolidated in federal MDL No. 3094 in Pennsylvania. A second MDL is forming around vision loss claims specifically. The litigation is in active discovery and moving faster than most pharmaceutical mass torts at this stage.

Here is everything you need to know.

What Is the Ozempic Lawsuit About?

The central legal claim is failure to warn. Plaintiffs allege that Novo Nordisk, the manufacturer of Ozempic and Wegovy, knew or should have known that semaglutide, the active ingredient in both drugs, could cause serious gastrointestinal injuries and vision loss, and failed to adequately disclose those risks on the drug's label.

This is the same legal theory that has driven major pharmaceutical mass torts for decades. When a company knows a drug can cause serious harm and chooses not to tell patients or their doctors, the law holds them accountable.

The Two Primary Injuries at the Center of the Litigation

Gastroparesis: Stomach Paralysis

Gastroparesis means the stomach cannot empty itself properly. Food sits. It does not move through the digestive system the way it should. The symptoms include severe nausea, vomiting, bloating, pain, and an inability to eat normally.

For some Ozempic patients, these symptoms began while taking the drug and did not resolve after stopping. The condition became chronic. Some required hospitalization, feeding tubes, or surgical intervention.

GLP-1 drugs like Ozempic work by slowing gastric emptying as part of their mechanism. Plaintiffs argue that Novo Nordisk knew this slowing could, in some patients, become severe and permanent, and failed to warn adequately.

NAION: Sudden, Irreversible Vision Loss

Nonarteritic anterior ischemic optic neuropathy, NAION, is a condition in which blood flow to the optic nerve is suddenly blocked, causing rapid vision loss that does not reverse. It can affect one eye or both.

Plaintiffs in the vision loss track allege that Ozempic use was linked to their NAION diagnosis. One case that gained significant attention involved a North Carolina woman who alleged permanent vision loss she attributed to Ozempic use. These cases are now being organized into a separate track within the MDL specifically because the injuries are severe and the claims are distinct from the gastrointestinal cases.

Over 140 NAION vision loss cases are already inside the Ozempic MDL. Plaintiffs' leadership has requested a separate Vision Injury Track for these claims due to the severity and distinct nature of the injury.

Where the Litigation Stands: May 2026

• More than 3,546 cases are consolidated in MDL No. 3094 in the Eastern District of Pennsylvania.

• Case counts surged by more than 500 new filings in a single month earlier in 2026, one of the most dramatic single-month increases in any active mass tort.

• Discovery is underway. No bellwether trials have been scheduled yet.

• A second MDL is forming around vision loss and NAION claims specifically.

• No global settlement has been reached. Legal analysts project the litigation is two or more years from resolution.

The rapid case count growth signals that awareness of qualifying injuries is accelerating. The cases filed now are the ones best positioned when bellwether trials eventually set settlement benchmarks.

Projected Settlement Amounts

No Ozempic settlements have been finalized as of May 2026. The following are projections from legal analysts based on comparable pharmaceutical mass tort outcomes including Vioxx, Zantac, and opioid litigation.

• Moderate injury cases (gastroparesis with hospitalization, documented treatment): projected $50,000 to $400,000.

• Severe injury cases (permanent gastroparesis, surgical intervention, NAION vision loss): projected $400,000 to over $700,000.

• Some analysts project the highest-severity individual cases could reach $2,000,000 or more, particularly where vision loss is permanent and the plaintiff is younger with significant economic losses ahead.

Early filers in pharmaceutical mass torts historically receive stronger settlement consideration. Defendants are often more willing to offer favorable terms to early cases that participate in bellwether selection.

Who May Qualify to File an Ozempic Lawsuit

• You were prescribed Ozempic, Wegovy, Mounjaro, or another GLP-1 receptor agonist.

• You developed gastroparesis, cyclic vomiting syndrome, bowel obstruction, or another serious gastrointestinal condition.

• Or you were diagnosed with NAION or experienced sudden, significant vision loss during or after use.

• Your diagnosis was not adequately disclosed as a risk by your prescribing physician based on the drug's labeling at the time.

You do not need to have taken the drug long-term. Some plaintiffs developed serious symptoms within a relatively short period of use.

Other GLP-1 Drugs Included

The Ozempic litigation also covers other GLP-1 drugs containing semaglutide or similar active compounds:

• Wegovy (semaglutide, Novo Nordisk, higher dose for weight loss)

• Mounjaro (tirzepatide, Eli Lilly)

• Zepbound (tirzepatide, Eli Lilly)

• Rybelsus (oral semaglutide)

If you took any of these medications and developed a qualifying condition, your situation may be eligible for review.

Get a Free Case Review

We Win Suits reviews Ozempic, Wegovy, and GLP-1 drug injury claims at no cost to you. If you or a family member developed gastroparesis, vision loss, or another serious condition after taking one of these medications, do not wait.

The litigation is moving. Case counts are growing. The window for filing is open now.

Visit wewinsuits.com to request your free case evaluation.

FREQUENTLY ASKED QUESTIONS

What is the Ozempic lawsuit about?

The Ozempic lawsuit alleges that Novo Nordisk failed to adequately warn patients and physicians about the risk of serious side effects, including gastroparesis (stomach paralysis) and NAION (sudden vision loss). More than 3,500 cases are consolidated in MDL No. 3094 in Pennsylvania.

What injuries qualify for an Ozempic lawsuit?

The primary qualifying injuries are gastroparesis (stomach paralysis), cyclic vomiting syndrome, bowel obstruction, and NAION (nonarteritic anterior ischemic optic neuropathy causing vision loss). Cases involving other serious gastrointestinal or neurological conditions linked to GLP-1 drug use may also qualify.

How much is an Ozempic lawsuit worth?

No settlements have been finalized as of May 2026. Legal analysts project individual settlements ranging from $50,000 for moderate cases to over $700,000 for severe cases. Vision loss and surgical cases may project higher. Actual amounts will depend on bellwether trial outcomes and individual case facts.

Does the Ozempic lawsuit cover Wegovy and Mounjaro?

Yes. The litigation covers semaglutide-based drugs including Wegovy and Rybelsus, and may include tirzepatide-based drugs like Mounjaro and Zepbound. If you took any GLP-1 drug and suffered a serious qualifying condition, your case may be eligible for review.

When will the Ozempic lawsuit settle?

Most legal analysts estimate the Ozempic MDL is at least two or more years from a global settlement, given it is still in early discovery with no bellwether trials scheduled. However, filing now positions your case for the strongest settlement consideration when negotiations begin.